AstraZeneca to Acquire Respiratory Portfolio from Takeda for $575M

Takeda Pharmaceutical Company Limited TKPYY today announced that it has entered into a definitive agreement to sell its respiratory portfolio to AstraZeneca AZN. In 2014 Takeda defined four therapeutic areas of focus: Gastroenterology, Oncology, Central Nervous System, and Cardiovascular and Metabolic. This divestiture will allow Takeda to work on becoming best-in-class in these therapeutic areas, while maintaining continuity of care for patients. "Patients are Takeda's primary focus and we are committed to working closely with AstraZeneca to ensure a smooth transition," said Christophe Weber, Chief Executive Officer, Takeda Pharmaceutical Company Limited. "AstraZeneca has extensive experience in respiratory care and will be able to prioritize getting these important medicines to the patients See full press release